Hematology Billing Experts

Hematology Medical Billing Services

Hematology billing combines complex diagnostic workups with high-cost drug administration.

Get Your Free Assessment Explore the Guide
Hematology Medical Billing Services
94%

First-Pass Clean Claim Rate

$56K

Avg. Monthly Revenue Recovered

22 Days

Average Days to Payment

3.7%

Client Denial Rate

Overview

Expert Revenue Cycle Management for Complex Hematologic Care

Hematology billing combines complex diagnostic workups with high-cost drug administration. Bone marrow biopsies (38220-38222) and aspirations require documentation of the site, technique, and pathology review. Blood transfusion codes (36430) and therapeutic phlebotomy (99195) have specific documentation requirements regarding medical necessity and the volume of blood products administered.

Coagulation management, including anticoagulant therapy monitoring, generates recurring billing through prothrombin time testing (85610) and INR management. Hematology practices that administer chemotherapy or biologic agents face the same drug reimbursement challenges as oncology, with J-code billing, buy-and-bill economics, and extensive prior authorization requirements.

Expert Revenue Cycle Management for Complex Hematologic Care
Challenges

Common Hematology billing Challenges We Solve

Every Hematology billing team deals with payer delays, coding nuance, and collection leakage.

Drug Buy-and-Bill Revenue Management

Hematology practices purchase expensive drugs (factor concentrates, monoclonal antibodies, chemotherapy agents) and bill payers for reimbursement. The spread between acquisition cost and ASP-based reimbursement must be carefully managed, and delayed payment on high-cost drug claims creates significant cash flow pressure.

Chemotherapy Administration Coding

Chemotherapy administration codes (96401-96417) vary based on the route (IV push, IV infusion, subcutaneous), whether the drug is the initial or sequential substance, and the duration of infusion. Multi-drug regimens create complex coding scenarios where the sequence of administration determines which codes apply.

Bone Marrow Procedure Billing

Bone marrow aspiration (38220) and biopsy (38222) can be billed separately or together, with specific documentation requirements for each. When performed with flow cytometry (88184-88189) or cytogenetic studies, the pathology and lab components must be coordinated to avoid duplicate billing.

Coagulation Testing and Monitoring

Patients on anticoagulation therapy require frequent monitoring with PT/INR (85610), PTT (85730), and specialized coagulation factor assays (85220-85293). Billing for anticoagulation management (99363-99364) adds another revenue stream, but documentation of time and clinical decision-making is required.

Services

Complete Hematology billing Services

Support spans the full revenue cycle.

Chemotherapy administration coding (96401-96417)

Drug buy-and-bill management with ASP tracking

Bone marrow aspiration and biopsy billing (38220, 38222)

Coagulation study coding (85610-85732)

Flow cytometry billing coordination (88184-88189)

Prior authorization for high-cost hematologic therapies

Coverage

Serving Hematology billing Teams Nationwide

We support independent practices and growing provider organizations.

Independent physician groups

Multi-location practices

Private equity backed platforms

Hospital-owned outpatient groups

Guide

The Complete Guide to Hematology billing

Hematology Medical Billing Overview

Picture a community hematology practice in Ohio. The billing coordinator opens Monday’s denial queue and finds seventeen claims from the prior week flagged by UnitedHealthcare, all tied to chemotherapy administration coding. Each claim had the right diagnosis. Each claim had the right drug code. But the infusion time documentation did not match the billed units on the claim form, and now the practice faces a recoupment request for the entire batch. That scenario plays out in hematology practices across the country because the gap between clinical documentation and billing translation is widest in oncology-adjacent specialties. Hematology sits squarely in that gap. The specialty covers the full spectrum from routine anemia management to complex bleeding disorders, bone marrow transplant evaluation, and hematologic malignancy treatment, and each service line carries its own payer rules, documentation requirements, and billing codes.

Medicare Part B covers the majority of hematology services for older adults, with Part D handling specialty drug coverage for oral agents like hydroxyurea and imatinib. Commercial payers including Aetna, Cigna, and BCBS apply prior authorization requirements to biological agents, colony-stimulating factors, and clotting factor products that can delay treatment starts and create authorization-to-billing timeline mismatches. Medicaid coverage for hematology varies dramatically by state, with some states covering comprehensive coagulation management and others restricting coverage to acute care episodes only.

Common Billing Challenges in Hematology

  • Infusion time documentation and unit calculation: Chemotherapy and biological infusion codes are billed in time-based units. When nursing notes record start and stop times inconsistently, or when the billed units do not match the calculated infusion duration, payers including Humana and UnitedHealthcare deny the claim or adjust reimbursement to the documented time, often without notification.
  • Drug code accuracy for specialty biologics: HCPCS J-codes for hematology agents such as J2505 (pegfilgrastim), J0897 (denosumab), and J7315 (factor VIII) must be billed with exact units per milligram as documented in the pharmacy dispensing record. Rounding errors or unit mismatches trigger automatic claim edits that delay payment by 30-45 days.
  • Prior authorization expiration during treatment cycles: Biological agents for myeloma, lymphoma, and coagulation disorders require authorization renewal every 60-90 days at most commercial payers. Treatment cycles that cross an authorization period without a renewal trigger denial of the entire cycle’s claims, not just the out-of-period dates.
  • Incident-to billing compliance for midlevel providers: Hematology practices frequently use nurse practitioners and physician assistants for chemotherapy monitoring visits. Billing these visits incident-to under the supervising physician’s NPI requires direct physician presence in the suite, not just the building. Documentation of supervision level is audited frequently by Medicare contractors.

Key CPT Codes for Hematology Billing

  • CPT 96413: Chemotherapy administration, intravenous infusion, first hour; the primary infusion code for IV chemotherapy delivery requiring documented start and stop times
  • CPT 96415: Chemotherapy administration, intravenous infusion, each additional hour; billed in addition to 96413 for infusions exceeding one hour, with time documented per additional unit
  • CPT 85025: Complete blood count with differential; the most frequently ordered hematology lab test, billed under the practice’s CLIA number when performed in-house
  • CPT 38221: Diagnostic bone marrow biopsy; requires fluoroscopy or ultrasound guidance documentation when imaging is used; bilateral billing requires Modifier 50 and separate documentation
  • CPT 86355: B cells, total count; flow cytometry for lymphocyte subset analysis; requires medical necessity documentation linking the test to a specific diagnostic question

Revenue Cycle Considerations for Hematology

A hematology practice running a mix of infusion services, bone marrow procedures, and outpatient management visits typically sees A/R days between 38 and 52 days. Infusion services drive the longest A/R when drug prior authorizations are not renewed before the cycle starts. The cost of a single denied biological infusion claim can run from $4,000 to $28,000 depending on the agent, making denial prevention in hematology a direct revenue protection function, not just an administrative task. Practices that implement real-time authorization tracking against scheduled infusion dates reduce biological agent denial rates by 30-40% compared to those tracking authorizations manually or not at all.

Medicare Part B reimburses at ASP plus 6% for most infused biologics, but sequestration reduces that to ASP plus 4.3% in practice. Commercial payers often reimburse at contracts pegged to AWP minus a percentage, which can result in actual drug cost exceeding reimbursement for high-cost agents if contracts are not renegotiated as drug pricing shifts. Practices should review drug cost versus reimbursement quarterly, not annually, to avoid systematic underpayment on their highest-cost treatment lines.

How My Medical Bill Solution Helps Hematology Practices

My Medical Bill Solution builds hematology billing workflows around infusion time documentation audit, drug unit verification against pharmacy dispensing records, and authorization renewal calendars keyed to each patient’s treatment cycle. Before any claim for a biological agent goes out the door, the billed units are cross-checked against the nursing note and the pharmacy record. Authorization renewal triggers are built into the workflow 30 days before each payer’s expiration date, so no infusion cycle starts without confirmed coverage.

Denial management for hematology includes J-code dispute resolution, NCCI edit appeals for same-day services, and incident-to compliance review for midlevel provider billing. The team understands the difference between a technical denial that can be corrected and resubmitted and a coverage denial that requires peer-to-peer review with the payer’s medical director. Contact My Medical Bill Solution to discuss how your hematology practice can reduce infusion-related denials and recover revenue on outstanding claims.

Common Questions

Frequently Asked Questions About Hematology billing

Answers to the questions practice owners ask most often.

We track each drug's ASP-based reimbursement rate, verify that the HCPCS J-code and units billed match the dose administered, apply the JW modifier for discarded drug wastage, and monitor payment accuracy against contracted rates. We flag underpayments within 5 business days and file appeals with supporting documentation.

We sequence administration codes based on the order of drug administration, applying initial (96413), sequential (96415), and concurrent (96417) infusion codes correctly. For regimens combining IV push and IV infusion drugs, we ensure each administration type is coded separately and that time documentation supports the units billed.

Yes. Factor replacement products are high-cost therapies that require precise unit billing. We manage the authorization process, bill the correct HCPCS code for each factor product, track home infusion vs. office administration billing rules, and reconcile payments against the contracted reimbursement rate.

We bill the aspiration (38220) and biopsy (38222) as separately identifiable procedures when both are performed. We coordinate with the pathology lab to ensure cytology, flow cytometry, and cytogenetic studies are billed under the appropriate provider and that no components are duplicated between the hematologist and pathologist claims.

We submit prior authorizations for all high-cost hematologic therapies including chemotherapy regimens, biologic agents, and factor replacement products. Our team tracks authorization approvals and renewal dates, handles peer-to-peer reviews when initial requests are denied, and ensures active authorizations are in place before drug administration.

We bill transfusion administration codes (36430 for blood, 36440 for push transfusion) along with the appropriate blood product codes. We verify that pre-transfusion testing is documented and billed, track units administered, and manage the consent documentation required for transfusion billing.

READY TO GET STARTED?

Start Billing Smarter for Hematology billing

Get a revenue review and a clear action plan tailored to your practice.

Get Your Free Assessment

HIPAA Compliant · No Upfront Fees · No Long-Term Contracts